NEW YORK, Oct. 28, 2014 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential wrongdoing at FedEx Corporation ("FedEx" or the "Company") (NYSE: FDX).
The investigation focuses on whether the Company and its officers breached their fiduciary duties by causing or allowing FedEx to engage in improper conducted related to the shipment of illegal pharmaceuticals.
On July 10, 2014, FexEx was indicted by a federal grand jury in San Francisco in a 15-count indictment which included drug trafficking and the conspiracy to distribute controlled substances. The Company's alleged misconduct occurred despite the fact that United States drug enforcement officials had repeatedly warned the Company to cease the illicit transportation of pharmaceutical drugs.
Request more information now by clicking here: www.faruqilaw.com/FDX. There is no cost or obligation to you.
Take Action
If you currently own FedEx stock and have owned it since 2004 and would like to discuss your legal rights, please visit www.faruqilaw.com/FDX. You can also contact us by calling Stuart Guber toll free at (215) 277-5770 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding FedEx's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Attn: Stuart Guber
[email protected]
Telephone: (215) 277-5770
Logo - http://photos.prnewswire.com/prnh/20120119/MM38856LOGO
SOURCE Faruqi & Faruqi, LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article